Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
BMC Pregnancy Childbirth ; 22(1): 979, 2022 Dec 28.
Artigo em Inglês | MEDLINE | ID: mdl-36577949

RESUMO

BACKGROUND: Pregnant Mexican Americans (hereafter called Latinas) and Black/African American women are at increased risk for psychological distress, contributing to preterm birth and low birthweight; acculturative stress combined with perceived stress elevates depressive symptoms in Latinas. Based on our prior research using a psychoneuroimmunology framework, we identified psychological and neuroendocrine risk factors as predictors of preterm birth in Latina women that are also identified as risk factors for Black/African American women. METHODS/DESIGN: In this prospective, randomized controlled trial with parallel group design we will explore psychosocial, neuroendocrine, and birth outcome effects of the Mastery Lifestyle Intervention (MLI). The MLI is a culturally relevant, manualized, psychosocial, group intervention integrating two cognitive behavioral therapies for both pregnant Latinas and Black/African American women (total n = 221). Study inclusion criteria are: women with current pregnancy at 14-20 weeks gestation, ability to read and speak English or Spanish, self-identify as Latina of Mexican heritage or Black/African American, 18-45 years old, born in the US or Mexico, and currently living in the US. Participants must receive Medicaid or other government-supported insurance, and meet screening criteria for anxiety, depressive symptoms, or stress. Participants are randomly assigned to either the intervention (MLI) or usual care group (UCG) in groups of 6-8 participants that occur over 6 consecutive weeks. Data are collected at 3 time points: enrollment (14-20 weeks gestation), following treatment (20-26 weeks), and 6 weeks after treatment (32-36 weeks gestation). Additional outcome, mediating, and moderating data are collected from the electronic health record during pregnancy and at birth. Analyses will primarily use generalized linear mixed modeling (GLMM) to evaluate the relationships between predictors and outcomes. DISCUSSION: This RCT will test the efficacy of two combined third generation cognitive behavioral therapies (the MLI), given in a group format over 6 sessions, as compared to a usual prenatal care group, for both Latina and African American pregnant women. If efficacious, it may be provided as an adjunct to routine prenatal care and improve mental health, as well as babies being born too small and too soon. TRIAL REGISTRATION: The trial was retrospectively registered at ClinicalTrials.gov . Bethesda (MD): National Library of Medicine. Identifier NCT05012072 , Reducing Pregnancy Risks: The Mastery Lifestyle Intervention (MLI); August 19, 2021. The trial is currently recruiting participants.


Assuntos
Negro ou Afro-Americano , Nascimento Prematuro , Gravidez , Recém-Nascido , Feminino , Lactente , Humanos , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Nascimento Prematuro/prevenção & controle , Estudos Prospectivos , Hispânico ou Latino , Estilo de Vida , Parto , Ensaios Clínicos Controlados Aleatórios como Assunto
2.
Expert Rev Vaccines ; 8(10): 1329-31, 2009 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-19803754

RESUMO

The Phacilitate Vaccine Forum comprised numerous plenary sessions and panel discussions. The highlights of the meeting were the discussion of new adjuvant technologies able to specifically target the immune system to drive the response down the required route. Also of topical interest was a session on the challenges of the current influenza pandemic, and strategies for vaccination and control of the disease. Finally, the session covering vaccines for tropical and emerging infectious diseases highlighted some of the niche vaccines that are being developed, in particular those for dengue and West Nile viruses, which show great promise. In addition to scientific promise, the value proposition for vaccine development in a risk-averse economy was outlined, citing expected growth in the worldwide market of more than US$25 billion within 5 years. This proposition was supported by the overviews of disposable and 'flex factory' manufacturing technologies, providing cost and time efficiencies in product development, which are especially critical for the emerging markets.


Assuntos
Adjuvantes Imunológicos/uso terapêutico , Surtos de Doenças/prevenção & controle , Vacinas/administração & dosagem , Defesa Civil , Desenho de Fármacos , Indústria Farmacêutica/economia , Humanos , Vacinas contra Influenza/administração & dosagem , Vacinas/economia , Vacinas/provisão & distribuição
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...